MOTS-c and TB-500 face the evidence standards of FDA compounding review

What happened

FDA’s compounding advisory committee agenda paired two widely marketed peptides with specific nominated uses: TB-500 for wound healing and MOTS-c for obesity and osteoporosis. Both were considered as bulk drug substances for possible inclusion on the section 503A list.

What the record says

The agency’s process separates a substance’s biological rationale from the evidence needed to support compounded use. Reviewers consider identity, characterization, historical use, evidence of effectiveness and safety concerns, including immunogenicity and peptide-related impurities.

What it does not mean

The meeting did not convert either peptide into an approved drug. Advisory recommendations are non-binding and do not establish that a product sold under the same name has the same composition or quality as the substance reviewed.

Why it matters

For readers, the key distinction is between an interesting mitochondrial or tissue-repair mechanism and a reproducible, clinically supported drug product. The FDA process is designed to test that distance.